Claims
- 1. A peptide consisting essentially of the amino acid sequence of any one of SEQ ID NO:2-SEQ ID NO:21.
- 2. The peptide of claim 1, wherein said peptide is a (4,12; 7,15) bicycle having the sequence of SEQ ID NO:20.
- 3. The peptide of either claim 1 or claim 2, wherein said peptide consists of the amino acid sequence of any one of SEQ ID NO:2-SEQ ID NO:21.
- 4. A method for preventing or treating primary or metastatic cancer or polyps in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist having the sequence of any one of SEQ ID NO:2-SEQ ID NO:21.
- 5. A method for treating metastatic cancer in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist selected from the group consisting of: uroguanylin; guanylin; and E. coli ST peptide.
- 6. A method for treating primary cancers other than colon cancer in a patient, comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist selected from the group consisting of: uroguanylin; guanylin; and E. coli ST peptide.
- 7. The method of claim 4, wherein said peptide is a (4,12; 7,15) bicyclic peptide having the sequence of SEQ ID NO:20.
- 8. The method of claim 4, wherein said primary cancer is a member selected from the group consisting of the breast, colon, rectum, lung, ovary, pancreas, bladder, prostate, kidney or testis.
- 9. The method of any one of claims 4-8, further comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with said guanylate cyclase receptor agonist.
- 10. A method of treating a patient for colon cancer or polyps comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with uroguanylin, guanylin or E. coli ST peptide.
- 11. The method of claim 9 and 10, wherein said cGMP-dependent phosphodiesterase inhibitor is selected from the group consisting of suldinac sulfone, zaprinast, and motapizone.
- 12. A method for preventing or treating inflammation in a patient comprising administering to said patient an effective dosage of a guanylate cyclase receptor agonist having the sequence of any one of: SEQ ID NO:2-SEQ ID NO:21; uroguanylin; guanylin; or E. coli ST peptide.
- 13. The method of claim 12, wherein said peptide is a (4,12; 7,15) bicyclic peptide having the sequence of SEQ ID NO:20.
- 14. The method of claim 12, wherein said inflammation is an inflammatory disaese selected from the group consisting of: asthma; nephritis, hepatitis, pancreatitis, bronchitis and cystic fibrosis.
- 15. The method of claim 12, wherein said patient is treated for an inflammatory disorder of the gastrointestinal tract.
- 16. The method of claim 15, wherein said inflammatory disorder of the gastrointestinal tract is an inflammatory bowel disease selected from the group consisting of:
ulcerative colitis and Crohn's disease.
- 17. The method of claim 12, further comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with said guanylate cyclase receptor agonist.
- 18. The method of claim 17, wherein said cGMP-dependent phosphodiesterase is selected from the group consisting of suldinac sulfone, zaprinast, and motapizone.
- 19. A method of treating a patient for primary or metastatic cancer, polyps or inflammation comprising administering to said patient:
a) a guanylate cyclase receptor agonist peptide having the sequence of any one of: SEQ ID NOs:2-21; uroguanylin; guanylin; or E. coli ST peptide; and b) at least one compound selected from the group consisting of: a cGMP-dependent phosphodiesterase inhibitor; an anti-inflammatory agent; an antiviral agent; and an anticancer agent; wherein said guanylate cyclase receptor agonist and said compound are each administered in a therapeutically effective amount.
- 20. A pharmaceutical composition in unit dose comprising a guanylate cyclase receptor agonist peptide having the sequence of any one of SEQ ID NOs:2-21 present in a therapeutically effective amount.
- 21. A pharmaceutical composition in unit dose form comprising:
a) a guanylate cyclase receptor agonist peptide having the sequence of any one of: SEQ ID NOs:2-21; uroguanylin; guanylin; or E. coli ST peptide; and b) at least one compound selected from the group consisting of: a cGMP-dependent phosphodiesterase inhibitor, an anti-inflammatory agent, an antiviral agent and an anticancer agent; wherein said guanylate cyclase receptor agonist and said compound are each present in a therapeutically effective amount.
- 22. The pharmaceutical composition of either claim 20 or 21, wherein the unit dose form is selected from the group consisting of a tablet, a capsule, a solution or inhalation formulation.
- 23. The pharmaceutical composition of either claim 20 nor 21, further comprising one or more excipients.
- 24. A method of inducing apoptosis in the cells of a subject, comprising administering to said subject an effective amount of agonist peptide having the sequence of any one of SEQ IDNO:2-SEQ IDNO:21.
- 25. A method of inducing apoptosis in the cells of a subject, comprising administering to said subject an effective amount of uroguanylin, guanylin or E. coli ST peptide for cancers other than colon cancer.
- 26. A peptide conjugate comprising polyethylene glycol (PEG) attached to a peptide having the sequence of any of: SEQ ID NO:2-SEQ ID NO:21; uroguanylin; guanylin; or E. coli ST peptide.
- 27. A method of treating cancer, inflammation or polyps in a patient comprising administering to said patient a therapeutically effective amount of the peptide conjugate of claim 26.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S. provisional application No. 60/279,438, filed on March29, 2001; No. 60/279,437, filed on March29, 2001; No. 60/300,850, filed on Jun. 27, 2001; No. 60/303,806, filed on Jul. 10, 2001; No. 60/307,358, filed on Jul. 25, 2001; and No. 60/348,646, filed on Jan. 17, 2002.
Provisional Applications (6)
|
Number |
Date |
Country |
|
60279438 |
Mar 2001 |
US |
|
60300850 |
Jun 2001 |
US |
|
60307358 |
Jul 2001 |
US |
|
60279437 |
Mar 2001 |
US |
|
60303806 |
Jul 2001 |
US |
|
60348646 |
Jan 2002 |
US |